A prospective study to evaluate the effect of the Molecular Adsorbent Recirculating System (MARS®) for patients with acute liver failure: a randomized controlled study

Gambro Korea Ltd (Korea, South)0 个研究点目标入组 50 人开始时间: 2014年1月8日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Acute liver failure patient in accordance with American Association for the Study of Liver Diseases (AASLD) guideline
•2. Age between 20 and 70
•3. Patient with a sign of hepatic encephalopathy
•4. If a patient is able to make decisions on his/her own, a subject?s own consent and signature is required. However, if a patient is unable to make decisions on his/her own due to hepatic coma, a consent and signature by a legal representative is required.
•5. All of the above
•6. Or acute-on-chronic liver failure (AoCLF) with hepatitis B including No. 2, 3 and 4 above

•1. Acute liver failure due to acetaminophen
•2. Acute hepatitis A
•3. Patient with a sign of hepatic encephalopathy due to alcoholic hepatitis
•4. Patient with anamnesis of chronic liver disease (except hepatitis B)
•5. Among autoimmune disease patients with abrupt recurrence, those who display varix and nodularity on CT or duodenoscopy
•6. Patient with anamnesis of hepatocirrhosis (except hepatitis B)
•7. Septic shock
•8. Patient with irreciprocal multiorgan failure
•9. Abrupt bleeding
•10. Pregnant or lactating women
•11. Patient whose mean arterial pressure (MAP) is below 55 mmHg despite usage of hypertensor
•12. Coma of non-hepatic origin
•13. Uncontrollable sepsis
•14. Extrahepatic cholestasis
•15. Extrahepatic neoplasia
•16. Patient with irreciprocal brain/organ damage leading to transplantation rejection syndrome
•17. HIV hepatitis

发起方

Gambro Korea Ltd (Korea, South)